Impact of Prebiotics in Ulcerative Colitis

Last updated: April 28, 2025
Sponsor: University of California, Los Angeles
Overall Status: Active - Recruiting

Phase

N/A

Condition

Ulcers

Inflammatory Bowel Disease

Crohn's Disease

Treatment

Prebiotic

Clinical Study ID

NCT06495658
24-000256
  • Ages 18-85
  • All Genders

Study Summary

The cause of inflammatory bowel disease (IBD) is currently unknown, although partly attributed to interactions among genetic risk polymorphisms, environmental factors, gut microbiome, and host immunity. Diet, particularly those with plant-based products, have been shown in prior research to improve gut microbial composition, which has been linked to different IBD-related outcomes. This study is interested in evaluating the impact of prebiotics on gut microbiome composition and gut health in patients with IBD.

Dietary composition will be assessed at baseline and over the course of 16 weeks. Participants will be randomized to either consume an 8-week course of prebiotic supplementation beginning at week 0 or week 8. Stool samples will be collected at weeks 0 and 8. The stool will be analyzed for cross-sectional and longitudinal fecal microbial changes associated with different prebiotic and diet consumption patterns in the context of heterogeneous disease characteristics.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ages 18 to 85 years old

  • History of biopsy-proven ulcerative colitis (UC)

  • Active symptoms (SCCAI >2)

  • Concomitant use of 5-aminosalicylates, immunomodulators, and corticosteroids will bepermitted, although initiation or dose adjustment must not have occurred within 30days prior to enrollment.

  • Concomitant use of biologic therapy will be permitted, although initiation or doseadjustment must not have occurred within 60 days prior to enrollment.

  • Prior probiotics or other dietary supplements use is permitted but will be asked tobe discontinued during the course of the trial

Exclusion

Exclusion Criteria:

  • Prior colectomy

  • Hospitalization

  • Urgent need for abdominal surgery

  • Unstable major medical condition

  • Active malignancy under treatment

  • Active alcohol or non-cannabinoid substance abuse

  • Pregnancy or lactation

  • Concerns for non-compliance

Study Design

Total Participants: 70
Treatment Group(s): 1
Primary Treatment: Prebiotic
Phase:
Study Start date:
July 09, 2024
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • UCLA

    Los Angeles, California 90095
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.